The short version
The US Vyleesi label covers premenopausal women with acquired, generalized hypoactive sexual desire disorder. It does not cover men, postmenopausal women or general sexual-performance enhancement.
Prescription status is product-specific. A recognized ingredient name does not make every preparation equivalent.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- PT-141
- Entry name · The name used for this encyclopedia topic.
- PT-141 (Bremelanotide)
- Recorded name variation · A name associated with this entry; check exact ingredient, modification, formulation and context.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
What should be clarified before interpreting claims?
The labeled autoinjector and indication do not establish equivalence of online preparations or an oxytocin blend.
Identity and evidence scope · DailyMed · Vyleesi prescribing information ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
The labeled autoinjector and indication do not establish equivalence of online preparations or an oxytocin blend.
Research terms in everyday language ↗
This is a bounded context overview, not a completed clinical literature appraisal. The linked source has the scope stated here; related-compound findings are not evidence for this preparation.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- Bremelanotide, commonly called PT-141, has a prescription-product use for a specific form of low sexual desire.
- Name variations
- Names you may see and important distinctions
- Source type
- US prescribing information
- Reference jurisdiction
- Research context; approval is product- and country-specific
A receptor is a structure that receives a chemical signal. An agonist activates a receptor. The mechanism section of the linked label explains the relevant pathway in greater detail.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗